Marshall Wace LLP Sells 69,487 Shares of CVRx, Inc. (NASDAQ:CVRX)

Marshall Wace LLP trimmed its position in CVRx, Inc. (NASDAQ:CVRX - Free Report) by 60.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 46,202 shares of the company's stock after selling 69,487 shares during the period. Marshall Wace LLP owned about 0.19% of CVRx worth $585,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jane Street Group LLC boosted its holdings in CVRx by 36.1% in the third quarter. Jane Street Group LLC now owns 19,038 shares of the company's stock valued at $168,000 after acquiring an additional 5,053 shares during the last quarter. Barclays PLC boosted its stake in shares of CVRx by 312.5% in the 3rd quarter. Barclays PLC now owns 19,067 shares of the company's stock valued at $169,000 after purchasing an additional 14,445 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of CVRx by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company's stock valued at $2,600,000 after purchasing an additional 6,443 shares during the last quarter. Calamos Advisors LLC acquired a new stake in shares of CVRx during the 4th quarter worth approximately $134,000. Finally, Bank of New York Mellon Corp raised its stake in shares of CVRx by 4.5% during the fourth quarter. Bank of New York Mellon Corp now owns 30,377 shares of the company's stock worth $385,000 after buying an additional 1,296 shares during the last quarter. 75.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have commented on CVRX shares. Canaccord Genuity Group lowered their target price on shares of CVRx from $23.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, April 8th. William Blair upgraded CVRx from a "market perform" rating to an "outperform" rating in a report on Tuesday, January 14th. Craig Hallum raised their target price on CVRx from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, January 17th. Lake Street Capital decreased their target price on CVRx from $19.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, April 8th. Finally, Piper Sandler increased their price target on shares of CVRx from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, CVRx currently has an average rating of "Buy" and a consensus target price of $17.60.

CVRx Stock Up 9.1 %

Shares of CVRx stock opened at $7.95 on Friday. CVRx, Inc. has a 1 year low of $5.81 and a 1 year high of $18.55. The company has a debt-to-equity ratio of 0.69, a current ratio of 12.06 and a quick ratio of 10.23. The company has a market capitalization of $207.15 million, a P/E ratio of -2.96 and a beta of 1.34. The business has a 50-day moving average of $9.87 and a two-hundred day moving average of $12.66.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its earnings results on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. As a group, equities analysts predict that CVRx, Inc. will post -1.91 EPS for the current year.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.